%0 Journal Article
%A Labadie, Julia D
%A Harrison, Tabitha A
%A Banbury, Barbara
%A Amtay, Efrat L
%A Bernd, Sonja
%A Brenner, Hermann
%A Buchanan, Daniel D
%A Campbell, Peter T
%A Cao, Yin
%A Chan, Andrew T
%A Chang-Claude, Jenny
%A English, Dallas
%A Figueiredo, Jane C
%A Gallinger, Steven J
%A Giles, Graham G
%A Gunter, Marc J
%A Hoffmeister, Michael
%A Hsu, Li
%A Jenkins, Mark A
%A Lin, Yi
%A Milne, Roger L
%A Moreno, Victor
%A Murphy, Neil
%A Ogino, Shuji
%A Phipps, Amanda I
%A Sakoda, Lori C
%A Slattery, Martha L
%A Southey, Melissa C
%A Sun, Wei
%A Thibodeau, Stephen N
%A Van Guelpen, Bethany
%A Zaidi, Syed H
%A Peters, Ulrike
%A Newcomb, Polly A
%T Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location.
%J JNCI cancer spectrum
%V 4
%N 5
%@ 2515-5091
%C Oxford
%I Oxford University Press
%M DKFZ-2020-01862
%P pkaa042
%D 2020
%X Postmenopausal hormone therapy (HT) is associated with a decreased colorectal cancer (CRC) risk. As CRC is a heterogeneous disease, we evaluated whether the association of HT and CRC differs across etiologically relevant, molecularly defined tumor subtypes and tumor location.We pooled data on tumor subtypes (microsatellite instability status, CpG island methylator phenotype status, BRAF and KRAS mutations, pathway: adenoma-carcinoma, alternate, serrated), tumor location (proximal colon, distal colon, rectum), and HT use among 8220 postmenopausal women (3898 CRC cases and 4322 controls) from 8 observational studies. We used multinomial logistic regression to estimate odds ratios (OR) and 95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:32923935
%2 pmc:PMC7477374
%R 10.1093/jncics/pkaa042
%U https://inrepo02.dkfz.de/record/163159